Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,589.17 +974.50 (+1.42%) CMC Crypto 200
1,517.21 +28.67 (+1.93%)
TRVI May 2024 6.000 put
| Previous close | 2.6000 |
| Open | 2.9000 |
| Bid | 3.1000 |
| Ask | 5.0000 |
| Strike | 6.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.6000 - 2.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Insider MonkeyTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript May 11, 2024 Trevi Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the Trevi Therapeutics First Quarter 2024 Earnings Conference Call. At this time, […]
PR NewswireTrevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor, business development and medical conferences in May and June.
- Thomson Reuters StreetEvents
Q1 2024 Trevi Therapeutics Inc Earnings Call
Q1 2024 Trevi Therapeutics Inc Earnings Call
